The conserved Myb-MuvB (MMB) multiprotein complex has an important role in transcriptional activation of mitotic genes. MMB target genes are overexpressed in several different cancer types and their elevated expression is associated with an advanced tumor state and a poor prognosis. This suggests that MMB could contribute to tumorigenesis by mediating overexpression of mitotic genes. However, although MMB has been extensively characterized biochemically, the requirement for MMB in tumorigenesis in vivo has not been investigated. Here we demonstrate that MMB is required for tumor formation in a mouse model of lung cancer driven by oncogenic K-RAS. We also identify a requirement for the mitotic kinesin KIF23, a key target gene of MMB, in tumorigenesis. RNA interference-mediated depletion of KIF23 inhibited lung tumor formation in vivo and induced apoptosis in lung cancer cell lines. Our results suggest that inhibition of KIF23 could be a strategy for treatment of lung cancer.
INTRODUCTION
Mitotic proteins, such as spindle checkpoint proteins, key mitotic kinases and proteins required for cytokinesis, are frequently expressed at elevated levels in cancer cells. Increased expression of mitotic proteins is probably, at least in part, due to a higher fraction of proliferating cells in tumor tissue. However, many mitotic genes that are expressed at elevated levels in tumors are part of recently published chromosomal instability (CIN) signatures that predict the clinical outcome of various cancer types independent of the cell cycle score. [1] [2] [3] Thus, elevated expression of some of mitotic genes could have a causal role in tumor initiation or progression due to the abnormal execution of mitosis, resulting in defects in chromosome segregation and aneuploidy. Mouse models have confirmed that the overexpression of mitotic proteins such as the spindle checkpoint protein MAD2 or the kinetochore protein HEC1 is sufficient to generate aneuploidy and to induce various tumors including lung adenomas. 4, 5 Several causes for the overexpression of mitotic genes in cancer cells have been identified. For example, inactivation of the retinoblastoma tumor suppressor protein leads to abnormal expression of MAD2 by E2F transcription factors. 6 Similarly, the c-MYC oncogene activates BUBR1 and MAD2, which in turn provoke a prometaphase delay that underlies the chromosomal missegregation induced by c-MYC. 7 Another key regulator of mitotic genes is the Myb-MuvB (MMB) complex (reviewed in Sadasivam and DeCaprio 8 ) . MuvB is the core of an evolutionary conserved complex that regulates transcription during the cell cycle. Specifically, in quiescent cells, MuvB, consisting of LIN9, LIN37, LIN52, LIN54 and RBBP4, associates with the p130 pocket protein and with E2F4 to form DREAM, which represses transcription. 9, 10 In contrast, in S phase, the interaction of the MuvB core with p130/E2F4 is lost and MuvB now binds to the B-MYB transcription factor to form the MMB complex. [10] [11] [12] In late S-phase, the transcription factor FoxM1 is also recruited into the complex. 11 In contrast to DREAM, MMB and MMB-FoxM1 act as transcriptional activators. Genome-wide expression studies and chromatin immunoprecipitation (ChIP) assays revealed that MMB and FoxM1 regulate late cell cycle genes with functions in mitosis and cytokinesis such as PLK1, cyclin B or the kinesin KIF20A, and that its inactivation results in mitotic defects. [11] [12] [13] [14] [15] Interestingly, at least 10 out of 29 mitotic genes included in the abovementioned CIN signature of lung, brain and breast tumors are directly regulated by MMB and FoxM1. Thus, MMB could promote tumorigenesis by activating the expression of critical mitotic genes.
The relationship of MMB to tumorigenesis is largely unknown and whether MMB contributes to tumorigenesis in vivo has not directly been tested. Here we used a mouse model of lung cancer driven by oncogenic K-RAS and loss of p53 to investigate the requirement for MMB during tumorigenesis in vivo. We find that MMB is required for lung tumor development, and that MMB drives the expression of mitotic kinesins in lung cancer cells. Depletion of the mitotic kinesin KIF23, one of several genes regulated by MMB, inhibits lung tumorigenesis and induces apoptosis in vitro and in vivo. Together, these data establish a requirement for MMB-regulated genes for lung tumorigenesis.
RESULTS

MMB is required for lung tumor formation in vivo
Little is known about the role of MMB in cancer in vivo. To investigate whether MMB is involved in lung tumorigenesis, we used a well-characterized in vivo mouse model of non-small cell lung cancer driven by oncogenic K-RAS and loss of p53.
This mouse model is based on a conditional allele of oncogenic KRas (LSL-K-Ras G12D ) and conditional loss-of-function p53 alleles (p53 fl/fl ) ( Figure 1a ). Controlled activation of oncogenic K-RAS G12D and loss of p53 in the lung is achieved by adenoviral or lentiviral Cre-recombinase, leading to the development of atypical adenomatous hyperplasias, adenomas, adenocarcinomas and invasive adenocarcinomas in the lungs within 13 weeks (Supplementary Figure S1) . 16, 17 B-MYB expression was induced during this process as demonstrated by immunohistochemistry with an antibody that detects active B-MYB phosphorylated on threonine 487 by cyclin A/CDK2 (Figure 1b) . 11, 18 In contrast, in normal lung, no phospho-B-MYB expression could be detected. In tumors, phospho-B-MYB was expressed at higher levels in advanced-stage adenocarcinomas (grade 3 and 4) compared with adenomas (grade 2) and lowgrade atypical adenomatous hyperplasias (grade 1) (Figures 1c  and d) . B-MYB (phospho-T487) immunohistochemistry in 11 human adenocarcinomas of the lung showed moderate to strong protein expression in all tumors (representative stainings shown in Figure 1e ), suggesting that it might have a role in lung tumorigenesis. Examination of previously published microarray data sets showed that high expression levels of B-MYB or of the MMB subunit LIN9 were associated with poor prognosis of lung adenocarcinoma patients (Figure 1f) . Furthermore, B-MYB protein expression was higher in lung cancer cell lines compared with non-transformed control cell lines (Figure 1g ).
To directly address the relevance of these findings for tumor initiation and progression in vivo, we crossed LSL-K-Ras fl/fl mice showed a lower tumor grade. Based on these data we conclude that MMB is required for lung cancer driven by oncogenic K-RAS in vivo. The relative tumor area in mice that retain one allele of B-Myb was comparable to that observed in control animals, suggesting that loss of one allele of B-Myb does not influence tumorigenesis. In contrast, relative tumor burden in heterozygous Lin9 fl/fl mice was slightly increased compared with Lin9 +/+ mice. Although the difference did not reach statistical significance, this might suggest that Lin9 can behave as a haploinsufficient tumor suppressor and as an oncogene in the same tumor type, similar to what has been observed for KLF4. 20 Next, to assess the efficiency of Cre-mediated recombination in tumors we determined the status of the B-Myb and Lin9 alleles by genomic PCR. In all tumors from LSL-K-Ras (Figures 4a and b) . Significantly, deletion of Lin9 strongly impaired the proliferation rate of KPL cells, whereas the addition of 4-OHT had no effect on the proliferation of control cells (Figures 4c and  d) . Microscopic examination showed that treatment with 4-OHT resulted in a high frequency of cellular abnormalities including multipolar mitosis, cells with multilobed nuclei and binucleated cells indicative of cytokinesis failure (Figure 4e and Supplementary Figure S2 ). Thus, loss of Lin9 in lung adenocarcinoma cells leads to nuclear abnormalities and a strong growth inhibition, providing a mechanistic explanation for the inhibitory effect of Lin9 deletion on lung tumorigenesis in vivo.
Mitotic genes are targets of MMB in lung cancer cells Previous microarray and ChIP experiments have identified mitotic genes such as the kinesin KIF23 (MKLP1), NUSAP1 and Survivin (BIRC5) as direct transcriptional targets of MMB. 14, 15, 24 To analyze the regulation of mitotic gene expression by MMB in lung cancer cells and to determine the relationship with p53, we used a cell line derived from mouse lung adenocarcinomas with oncogenic KRas G12D and a non-functional p53 allele, which is blocked by a translational STOP cassette that can be removed by an inducible CreER T2 recombinase. 25 The addition of 4-OHT to the cell culture medium activates CreER T2 recombinase and results in re-expression of p53 (Figure 5b ). Depletion of B-MYB or LIN9 in KPR8 cells (before p53 restoration) by RNA interference reduced the expression of six mitotic kinesins and four other MMB genes (CENPF, PLK1, BIRC5 and NUSAP1) with functions in mitosis ( Figure 5a ).
Restoration of the p53 allele by addition of 4-OHT induced p53 protein expression and strongly activated p21 CIP1 , a cyclin- (Figure 5d ). Consistent with these findings, ChIP assays showed that binding of B-MYB to the promoters of NUSAP1 and CENP-F was strongly reduced after p53 restoration, whereas binding of p130 was induced ( Figure 5e ). These changes correlate with reduced expression of NUSAP1 and CENP-F after p53 restoration. RNA interference-mediated depletion of MMB subunits LIN9 and B-MYB, and ChIP experiments in the human lung adenocarcinoma cell line H23 confirmed that MMB is required to drive overexpression of mitotic genes (Supplementary Figure S3) . Together, these data suggest that MMB drives expression of mitotic genes in lung carcinoma cells in the absence of functional p53. Consistent with this notion, immunohistochemistry showed that Nusap1 is expressed in murine lung adenocarcinomas, and that its expression correlated with tumor grade (Supplementary Figure S4) . Furthermore, there is a high correlation between the expression of B-MYB and the MMB target gene Nusap1 in individual lung adenocarcinomas in vivo (Figure 5f ).
The MMB regulated mitotic kinesin KIF23 is required for proliferation of lung cancer cells and for tumor formation in vivo Although these observations suggest that MMB might be a therapeutic target for the treatment of lung cancer, inhibiting its function with small molecules will be difficult to achieve, as no enzymatic activities have been identified in the complex. Mitotic kinesins are targets of MMB in lung cancer cells ( Figure 5 and Supplementary Figure S3) . They have emerged as potential new drug targets given their association with CIN signatures and the correlation of their expression with poor clinical outcome. 26, 27 Therefore, we next selected the MMB-regulated mitotic kinesin KIF23 (MKLP1) for a more detailed characterization. 24 KIF23, a kinesin of the kinesin-6 family, is a subunit of the centralspindlin For all panels: *, ** or *** indicates that the differences were statistically significant; *Po0.05; **P o0.001, *** P o0.0001; Student's t-test; two-sided. complex that is critical for formation of the central spindle. 28 To assess the therapeutic effect of inhibiting KIF23, we used a multifunctional lentiviral vector to establish several stable lung cancer cell lines that express doxycycline-inducible small hairpin RNAs (shRNAs) directed at KIF23 (Figure 6a) . As on addition of doxycycline red fluorescent protein (RFP) is co-expressed together with the shRNA, we first measured the expression of RFP after treatment with different concentrations of doxycycline, to growth of lung cancer lines by treatment of the stable cell lines with different concentrations of doxycycline and by assaying cell number using crystal violet staining. Proliferation of all four cell lines was inhibited by KIF23 depletion (Figure 6c and Supplementary Figure S7A ). The two cell lines H23 and HOP92 were most sensitive to KIF23 depletion and their growth was strongly inhibited even at low concentrations of doxycycline ( Figure 6c ). As determined by fluorescence-activated cell sorting, the sub G1 population, indicative of degraded DNA, a hallmark of apoptosis, was also strongly increased in these two cell lines following KIF23 depletion (Figure 6d ). Microscopic examination demonstrated that depletion of KIF23 increased the number of cancer cells with abnormal nuclei such as binucleated cells, multinucleated cells and giant multinucleated cells (Figure 6e and Supplementary Figure S7B) . In summary, our results indicate that depletion of KIF23 induces mitotic catastrophe as characterized by the formation of giant multinucleated cells followed by apoptotic cell death.
To test whether depletion of KIF23 can inhibit lung tumorigenesis in vivo, we used the K-RAS-dependent non-small cell lung cancer mouse model described above. For this purpose, we created a bifunctional lentivirus that expresses Cre recombinase and, in addition, an shRNA to knock down KIF23 (Figure 7a ). The shRNA is identical to the one used in human tumor cells due to conservation of the target sequence. Furthermore, the KIF23-specific shRNA resulted in efficient knockdown of the KIF23 mRNA in murine NIH-3T3 cells (Supplementary Figure 7C) . LSL-K-Ras G12D ; p53 fl/fl mice were infected with the bifunctional lentivirus to induce lung adenocarcinomas and simultaneously deplete KIF23. In parallel, LSL-K-Ras G12D ;p53 fl/fl mice were infected with a lentivirus expressing Cre recombinase and a control shRNA directed at luciferase. Mice were killed 14 weeks after tumor induction and lung tumors were analyzed histologically. Depletion of KIF23 significantly impaired lung tumor development, indicating a requirement for KIF23 in K-RAS-driven non-small cell lung cancer in vivo (Figures 7b-d) .
DISCUSSION MMB has been identified in previous studies as a master regulator of mitotic gene expression (for review, see Sadasivam et al. 8 ). MMB target genes and B-MYB itself are frequently expressed at elevated levels in tumors and their deregulation is associated with more advanced stages of the disease.
1,2 However, whether MMB contributes to cancer in vivo has not been analyzed. To address this issue, we have used a mouse model of lung adenocarcinoma induced by oncogenic K-RAS and loss of p53. We find that deletion of B-Myb or of Lin9, a core subunit of MuvB, inhibits tumor formation in this model. Mechanistically, we provide evidence that proliferation of lung cancer cells strongly depends on MMB, which acts to activate mitotic genes in these cells. We also show that transcriptional activation by MMB is antagonized by p53, corroborating earlier studies of indirect repression of mitotic genes by p53 through formation of DREAM. [29] [30] [31] Induction of p53 results in displacement of B-MYB from MMB and in formation of the repressive DREAM-p130 complex. Collectively, this suggests that MMB contributes to the upregulation of G2/M phase-specific genes in p53-negative cells. On the basis of our findings, one might consider MMB as a therapeutic target for the treatment of lung cancer. However, as no enzymes have so far been identified in the MMB complex, inhibiting its function with small molecules will be difficult to achieve. A promising new strategy that has recently emerged is degradation of multidomain scaffold proteins by ligand-induced protein degradation using bifunctional ligands. 32 Here, one part of the ligand is specific to the target protein, whereas the other part recruits a cellular E3 ligase that mediates proteasomal degradation of the target. However, the complete inhibition of MMB might be problematic, given that the deletion of B-Myb or Lin9 in mice is known to result in lethality. 15, 33 Limited inhibition of MMB might provide a therapeutic window to treat lung adenocarcinomas. An alternative approach would be to target the downstream targets of MMB such as the mitotic kinesin KIF23, which was investigated in this study.
Kinesins are ATP-dependent motor proteins that regulate the dynamic properties of microtubules. 26, 34 Of the 45 kinesins in the human genome, at least 16 have been implicated in coordinating mitosis and cytokinesis. They are responsible for the formation and function of the mitotic spindle, chromosome segregation and cytokinesis. Owing to their specialized functions in mitosis, mitotic kinesin inhibition might produce fewer side effects compared with microtubule targeting agents currently used in the clinic.
KIF23 belongs to the kinesin-6 family, whose members have non-redundant roles in cytokinesis. 26, 35 Expression of KIF23 has been shown to be upregulated in glioma and non-small cell lung cancer compared with normal tissues. 36, 37 In addition, KIF23 is associated with a signature of 100 genes whose elevated expression was associated with CIN and a poor prognosis across 6 different cancer types including breast cancer and colon cancer. 2 It is possible that the overexpression of KIF23 leads to defects in chromosome segregation, thereby contributing to CIN and aneuploidy, which is tightly associated with tumorigenesis. 38 Although these observations suggest that KIF23 plays a role in tumorigenesis, it has not yet been investigated whether it is required for tumor formation in vivo. Here we demonstrate that depletion of KIF23 inhibited lung tumor formation in vivo, similar to what is seen with deletion of MMB. In vitro, the depletion of KIF23 in lung cancer cell lines showed strong anti-proliferative activity, which was accompanied by apoptosis in a subset of cell lines. Cell death in response to KIF23 downregulation could contribute to the reduction in tumor size in vivo. Downregulation of KIF23 can inhibit proliferation of glioma cells, suggesting that KIF23 may be therapeutic target for additional tumor types in addition to lung cancer. 37 In future work, it will be important to assess the therapeutic potential of inhibiting KIF23 in already established tumors and to asses the toxicities for nontransformed cells.
MATERIALS AND METHODS Mice
All animals were maintained on a C57BL/6 background. LSL-K-RAS G12D , conditional p53, conditional B-Myb and conditional Lin9 knockout mice have been described. 15, 19, 39, 40 LSL-K-RAS G12D and conditional p53 mice were obtained from the NCI Mouse Repository, Bethesda, MD, USA. Tumors were initiated in 6-to 9-week-old male and female mice by nasal instillation of calcium phosphate precipitated adenovirus-Cre (Gene Transfer Vector Core, University of Iowa; 10 5 plaque-forming units per mouse) or by intra-tracheal infection of mice with a lentiviral vector expressing Cre-recombinase (10 6 lentiviruses per mouse) as described previously. 17, 41 Sample size was based on comparable studies in the literature. To deliver the virus, mice were anesthetized with Ketamin/ Xylazin. For infection with the Cre-shLuc (control) or Cre-shKIF23 lentivirus, LSL-K-RAS G12D ;p53 fl/fl mice were randomly allocated to two groups. All animal experiments were carried out according to protocols that were approved by an institutional committee (Tierschutzkommission der Regierung von Unterfranken).
Genotyping of mice, primary tumors and cell lines
The status of the K-Ras, B-Myb and Lin9 alleles in tumors and tumor cell lines was analyzed by PCR with previously described primers. 15, 19, 39 To determine the recombination of Lin9 and B-Myb in primary tumors, genomic DNA was isolated by scraping the tumor material with forceps into 1 ml pure Xylene. Samples were centrifuged for 5 min at full speed in a tabletop centrifuge at room temperature and washed twice with 1 ml absolute ethanol. Genomic DNA from the obtained pellet was further processed and genotyped.
Lentivirus production and titer determination Lentviruses were produced as described previously. 42 To determine the biological lentiviral titer, we first generated a Cre-reporter cell line by stably transfecting NIH-3T3 cells with the GFP-reporter plasmid pZ/EG. 43 For titer determination, the Z/EG reporter cell line (which expresses GFP after Cre-mediated recombination) was infected with serially diluted lentivirus. The fraction of GFP-positive cells was determined by fluorescenceactivated cell sorting.
Cell culture H23, H460, HOP62, HOP92, H226, H522, H358, H441 and A549 cells were cultured in RPMI containing 10% fetal calf serum (Invitrogen, Carlsbad, CA, USA). BJ, WI38 and KPR8 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal calf serum (Invitrogen). Human cell lines have been authenticated by the multiplex human cell line authentication test (Multiplexion, Heidelberg, Germany). To re-activate p53 in KPR8 cells, cells were treated with 500 nM 4-hydroxytamoxifen (Sigma, Munich, Germany) for the indicated time. 25 
Histopathology and immunohistochemistry
Mouse lung tissues were fixed in 4% paraformaldehyde in phosphatebuffered saline, embedded in paraffin and sectioned. Sections were deparaffinized, rehydrated and stained with hematoxylin and eosin or processed for immunohistochemistry staining. Tumor grading was performed in a blinded manner in accordance to the literature. 17 For immunohistochemistry, sections were incubated for 15 min with 3% H 2 O 2 , to quench endogenous peroxidase. Antigen retrieval was performed in 10 mM sodium citrate buffer (pH 6.0) by boiling in a microwave for 15 min. Slides were blocked with 3% bovine serum albumin in phosphate-buffered saline and incubated with relevant primary antibodies overnight at 4°C. Secondary antibody was applied to sections at 1:200, incubated for 60 min at room temperature and developed in diaminobenzidine. Human adenocarcinomas of the lung were stained immunohistochemically using the anti-B-MYB (phospho T487) antibody (clone EPR2204Y, rabbit monoclonal, 1:100 dilution, Abcam, Cambridge, UK) following antigen retrieval with pressure cooking (citric acid pH 6.0).
Isolation of tumor cell lines
KP and KPL cell lines were derived by enzymatic and mechanical dissociation of individual lung tumors as described previously. 44 Briefly, tumors were dissected under aseptic conditions and minced with sterile razor blades in 2 ml Trypsin/EDTA (0.25%) in a 100-mm cell culture dish. After 30 min of trypsinization at 37°C, the reaction was stopped with 10 ml fresh media. Tissue was broken up by pipetting and the cell suspension was cultured in media supplemented with Mouse FibrOut 9 (CHI Scientific, Maynard, MA, USA). Cells were cultured until confluency was reached, genotyped and stored for further processing.
Antibodies
The following primary antibodies were used: LIN9: ab62329 (Abcam); B-MYB: LX015.1 (kind gift from Roger Watson); 45 
Immunoprecipitation and immunoblotting
Cells were lysed in TNN (50 mM Tris (pH 7.5), 120 mM NaCl, 5 mM EDTA, 0.5% NP40, 10 mM Na 4 P 2 O 7 , 2 mM Na 3 VO 4 , 100 mM NaF, 10 mg/ml phenylmethylsulfonyl fluoride and protease inhibitors (Sigma)). Whole-cell lysates were immunoprecipitated with antibodies overnight at 4°C, bound to Protein-G-Sepharose for 2 h and washed five times with TNN lysis buffer. Proteins were separated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane and detected by immunoblotting.
Chromatin immunoprecipitation
Cells were cross-linked with 1% formaldehyde for 10 min at room temperature. The reaction was stopped by adding 125 mM glycine. Cells were lysed for 10 min in lysis buffer (5 mM PIPES (pH 8.0), 85 mM KCl, 0.5% NP40 and protease inhibitors (Sigma)). Nuclei were lysed in nuclei lysis buffer (50 mM Tris (pH 8.1), 10 mM EDTA, 1% SDS and protease inhibitors (Sigma)). Chromatin was sonicated to an approximate length of 250-500 bp, diluted 1:10 with dilution buffer (0.01% SDS, 1.1% Triton, 1.2 mM EDTA, 16.7 mM Tris (pH 8.2), 167 mM NaCl and protease inhibitors (Sigma)) and used for immunoprecipitation overnight. Immmunoprecipitates were collected with protein G-Dynabeads (Invitrogen) for 1 h (blocked with 1 mg/ml bovine serum albumin and 0.3 mg/ml singlestranded DNA). Beads were washed seven times with LiCl washing buffer (0.25 mM LiCl, 0.5% NP40, 0.5% sodium deoxycholate, 1 mM EDTA, 10 mM Tris (pH 8.0) and protease inhibitors (Sigma)) and eluted with elution buffer (50 mM Tris (pH 8.0), 1% SDS and 10 mM EDTA). The cross-link was reversed overnight with 0.2 mM NaCl at 65°C. After proteinase K incubation for 2 h at 55°C, chromatin was purified using Qiagen (Hilden, Germany) DNA purification spin columns and eluted in 50 μl. Chromatin (1 μl) was used as template for quantitative real-time PCR.
RNA interference
The small interfering RNAs targeting human and murine LIN9 and B-MYB have been described before.
12-14,29 Double-stranded RNA was purchased from MWG/Eurofins (Ebersberg, Germany). Small interfering RNAs were transfected in a final concentration of 50 nM using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol.
For inducible expression of a KIF23 shRNA in lung cancer cells, the lentiviral pINDUCER10 vector was first modified by replacing the puromycin resistance gene for a blasticidin resistance gene. 47 Next, a mir30-based shRNA specific for KIF23 was cloned into the vector. The targeting sequence for KIF23 is: 5′-CCCAGAGTTTGCAGATATGATA-3′. Lung cancer cell lines stably expressing KIF23-specific shRNA were generated by lentiviral infection and selection with blasticidin.
RNA isolation, reverse transcription and quantitative real-time PCR Total RNA was isolated with Total RNA Isolation Reagent (Invitrogen). One microgram of RNA was transcribed using 125 units MMuLv (Invitrogen). Quantitative real-time PCR reagents were from Invitrogen and real-time PCR was performed using the Mx3000 (Stratagene, Santa Clara, CA, USA) detection system. Expression differences were calculated as described before. 10 
Statistical analysis
Statistical analyses were performed using Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). Statistical significance was determined using Student's t-test. P-values o 0.05 were considered statistically significant. Survival analyses for human lung adenocarcinoma patients were computed using an online tool (http://kmplot.com using the 2015 version (n ¼ 2437) and excluding biased arrays). Log rank was automatically computed. 48 
